FC
| |
Finepoint Capital LP13F | |
| Finepoint Capital LP | |
| Last update 2025-05-14 | 25 Stocks (0 new) |
| Value $1.31 Bil | Turnover 0 % |
Finepoint Capital LP Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SPY
PUT
| SPDR S&P 500 ETF Trust | 755,000 | 422,173.3 | 0% | 32.200 | 0% | 0.070 | +18.80% | +8.86% | 654,366.5 | ||
QXO | QXO Inc | 24,468,160 | 331,298.9 | -1.87% | 25.270 | -0.45% | 4.720 | +77.61% | +39.18% | 14,834.5 | Software | |
IWM
PUT
| iShares Russell 2000 ETF | 1,485,000 | 296,257.5 | 0% | 22.590 | 0% | 0.490 | +19.15% | +2.59% | 65,690.6 | ||
LBRDK | Liberty Broadband Corp | 529,240 | 45,011.9 | -73.74% | 3.430 | -6.78% | 0.370 | +24.00% | +29.96% | 13,040.9 | Telecommunication Services | |
SWTX | SpringWorks Therapeutics Inc | 728,602 | 32,153.2 | -2.69% | 2.450 | -0.04% | 0.970 | +1.01% | +30.06% | 3,540.6 | Biotechnology | |
LLYVK | Liberty Live Group | 432,895 | 29,497.5 | -46.74% | 2.250 | -1.58% | 0.470 | +19.00% | +23.85% | 7,713.5 | Media - Diversified | |
ASND | Ascendis Pharma AS | 179,872 | 28,034.8 | -2.70% | 2.140 | -0.04% | 0.300 | +7.59% | +23.59% | 10,291.8 | Biotechnology | |
RVMD | Revolution Medicines Inc | 691,260 | 24,443.0 | -2.68% | 1.860 | -0.05% | 0.370 | +0.24% | -14.20% | 6,990.6 | Biotechnology | |
MLTX | MoonLake Immunotherapeutics | 435,785 | 17,026.1 | -2.71% | 1.300 | -0.04% | 0.690 | +41.08% | +2.94% | 3,538.1 | Biotechnology | |
GLPG | Galapagos NV | 656,587 | 16,493.5 | -2.69% | 1.260 | -0.03% | 1.000 | +30.55% | +21.05% | 2,193.8 | Biotechnology |
Finepoint Capital LP's Historical Top Holdings Breakdowns
Finepoint Capital LP's Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
LBRDK | Liberty Broadband Corp | 2025-03-31 | Reduce Reduce | -6.78% | 73.49 ($80.38) 88.64 | $90.95 | 13.15% | Reduce -73.74% | 529,240 | -1,486,470 | |
ARGX | argenx SE | 2025-03-31 | Sold Out Sold Out | -1.99% | 571 ($631.12) 671.75 | $575.42 | -8.83% | Sold Out | 0 | -52,928 | |
LLYVK | Liberty Live Group | 2025-03-31 | Reduce Reduce | -1.58% | 62.79 ($71.34) 80.35 | $84.29 | 18.15% | Reduce -46.74% | 432,895 | -379,897 | |
QXO | QXO Inc | 2025-03-31 | Reduce Reduce | -0.45% | 12.01 ($13.6) 16.1 | $22.13 | 62.72% | Reduce -1.87% | 24,468,160 | -465,665 | |
RVMD | Revolution Medicines Inc | 2025-03-31 | Reduce Reduce | -0.05% | 35.36 ($40.59) 44.42 | $37.53 | -7.54% | Reduce -2.68% | 691,260 | -19,000 | |
ASND | Ascendis Pharma AS | 2025-03-31 | Reduce Reduce | -0.04% | 119.49 ($142.85) 168.84 | $170.14 | 19.10% | Reduce -2.7% | 179,872 | -5,000 | |
MLTX | MoonLake Immunotherapeutics | 2025-03-31 | Reduce Reduce | -0.04% | 36.75 ($43.09) 53.57 | $55.74 | 29.36% | Reduce -2.71% | 435,785 | -12,150 | |
| SWTX Unlock Delisted | SpringWorks Therapeutics Inc | 2025-03-31 | Reduce Reduce | -0.04% | 32.5 ($46.03) 59.93 | $46.99 | 2.09% | Reduce -2.69% | 728,602 | -20,150 | |
GLPG | Galapagos NV | 2025-03-31 | Reduce Reduce | -0.03% | 22.69 ($25.27) 28.79 | $33.29 | 31.74% | Reduce -2.69% | 656,587 | -18,175 | |
SRPT | Sarepta Therapeutics Inc | 2025-03-31 | Reduce Reduce | -0.03% | 63.82 ($105.27) 127.89 | $13.32 | -87.35% | Reduce -2.7% | 157,555 | -4,380 |
Finepoint Capital LP Total Holding History ($B)
Finepoint Capital LP's Asset Allocation
Finepoint Capital LP Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Finepoint Capital LP's Hypothetical Growth since 2025-03-31
Finepoint Capital LP's Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Finepoint Capital LP's Holdings Heat Map
Size field:
Finepoint Capital LP's Holdings Bubble Chart
Finepoint Capital LP News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers